To investigate the role of FGFR1 in the regulation of p21 levels in ER + breast cancer cell lines, we used the pan-FGFR inhibitor TAS-120 (irreversible FGFR1-4 inhibitor) to block the effects of FGF2. Here, CDKN1A is linked to breast cancer.